JP7843707B2 - 肝星細胞への治療薬の脂質ナノ粒子送達のためのカチオン性脂質 - Google Patents

肝星細胞への治療薬の脂質ナノ粒子送達のためのカチオン性脂質

Info

Publication number
JP7843707B2
JP7843707B2 JP2022548450A JP2022548450A JP7843707B2 JP 7843707 B2 JP7843707 B2 JP 7843707B2 JP 2022548450 A JP2022548450 A JP 2022548450A JP 2022548450 A JP2022548450 A JP 2022548450A JP 7843707 B2 JP7843707 B2 JP 7843707B2
Authority
JP
Japan
Prior art keywords
mol
approximately
lipid
linear
sirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022548450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513698A (ja
JPWO2021163339A5 (https=
JP2023513698A5 (https=
Inventor
ヘイズ，ジェイムズ
モン ラム，キュー
ジェイ ホーランド，リチャード
ヂャン，ウェンシュエン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genevant Sciences GmbH
Original Assignee
Genevant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genevant Sciences GmbH filed Critical Genevant Sciences GmbH
Publication of JP2023513698A publication Critical patent/JP2023513698A/ja
Publication of JPWO2021163339A5 publication Critical patent/JPWO2021163339A5/ja
Publication of JP2023513698A5 publication Critical patent/JP2023513698A5/ja
Application granted granted Critical
Publication of JP7843707B2 publication Critical patent/JP7843707B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Optics & Photonics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022548450A 2020-02-11 2021-02-11 肝星細胞への治療薬の脂質ナノ粒子送達のためのカチオン性脂質 Active JP7843707B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062975116P 2020-02-11 2020-02-11
US62/975,116 2020-02-11
PCT/US2021/017676 WO2021163339A1 (en) 2020-02-11 2021-02-11 Cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells

Publications (4)

Publication Number Publication Date
JP2023513698A JP2023513698A (ja) 2023-04-03
JPWO2021163339A5 JPWO2021163339A5 (https=) 2024-02-21
JP2023513698A5 JP2023513698A5 (https=) 2024-02-21
JP7843707B2 true JP7843707B2 (ja) 2026-04-10

Family

ID=77292598

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548450A Active JP7843707B2 (ja) 2020-02-11 2021-02-11 肝星細胞への治療薬の脂質ナノ粒子送達のためのカチオン性脂質

Country Status (11)

Country Link
US (1) US20230139594A1 (https=)
EP (1) EP4103172A4 (https=)
JP (1) JP7843707B2 (https=)
KR (1) KR20220140531A (https=)
CN (1) CN115697321A (https=)
AU (1) AU2021218409A1 (https=)
BR (1) BR112022015803A2 (https=)
CA (1) CA3170547A1 (https=)
IL (1) IL295441A (https=)
MX (1) MX2022009861A (https=)
WO (1) WO2021163339A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3364949A4 (en) * 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
CN117045791B (zh) * 2023-03-22 2025-10-03 中国药科大学 肝星状细胞neu1的靶向过表达剂在制备治疗肝纤维化的药物中的应用
WO2025189064A1 (en) 2024-03-08 2025-09-12 Genzyme Corporation Lipid nanoparticles
JP2025168864A (ja) * 2024-04-30 2025-11-12 信越化学工業株式会社 含窒素多官能オルガノキシシラン化合物の製造方法
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
WO2026022656A2 (en) 2024-07-22 2026-01-29 Genevant Sciences Gmbh Lipid particle formulations with permanently charged cationic lipids
WO2026022677A1 (en) 2024-07-22 2026-01-29 Genevant Sciences Gmbh Permanently charged cationic lipids
WO2026030375A2 (en) 2024-07-30 2026-02-05 Genzyme Corporation Lipid nanoparticles and methods of manufacture and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009209311A (ja) 2008-03-06 2009-09-17 Kao Corp 機能性物質放出剤
WO2012166949A1 (en) 2011-05-31 2012-12-06 Regents Of The University Of Minnesota Silicate prodrugs and nanoparticles
CN102911401A (zh) 2012-11-08 2013-02-06 广州市回天精细化工有限公司 一种羟基清除剂、其制备方法及含有它的硫化硅橡胶
CN108239103A (zh) 2018-01-02 2018-07-03 深圳市广业电子科技有限公司 一种含有多肟基硅的硅氮化合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB709345A (en) * 1950-08-28 1954-05-19 California Research Corp Unsymmetrical alkoxy (tri- and tetra-) siloxanes and processes for making the same
US2713064A (en) * 1953-12-07 1955-07-12 Dow Corning Bis-(trialkoxysilyl) benzenes and their use
US3029269A (en) * 1956-08-21 1962-04-10 California Research Corp Silicon esters
DE1180359B (de) * 1962-05-15 1964-10-29 Ruhrchemie Ag Verfahren zur kontinuierlichen Herstellung von Orthokieselsaeureestern
NL134718C (https=) * 1966-12-01
US3810843A (en) * 1971-05-28 1974-05-14 Gen Electric Silicone-silica compositions
CH632765A5 (de) * 1977-09-09 1982-10-29 Ciba Geigy Ag Verfahren zur herstellung von siliciummodifizierten phthalsaeurederivaten.
US4329486A (en) * 1981-06-29 1982-05-11 Olin Corporation Process for preparing alkoxysilane cluster compounds by reacting a trialkoxysilanol with an amidated alkoxysilane cluster compound
JPH086040B2 (ja) * 1990-10-26 1996-01-24 信越化学工業株式会社 オルガノポリシロキサン組成物
US5534592A (en) * 1995-09-22 1996-07-09 The Goodyear Tire & Rubber Company High performance blend for tire treads
EP1687830B1 (en) * 2003-11-28 2010-07-28 Merck Patent GmbH Organic semiconducting layer formulations comprising polyacenes and organic binder polymers
JP5401316B2 (ja) * 2006-09-29 2014-01-29 モメンティブ パフォーマンス マテリアルズ インコーポレイテッド 加水分解性有機官能性シランの部分および／または完全縮合物の貯蔵に安定な組成物
JP5316743B2 (ja) * 2007-11-01 2013-10-16 Ｊｓｒ株式会社 ケイ素含有膜形成用組成物およびケイ素含有絶縁膜の形成方法
CN101724127A (zh) * 2008-10-16 2010-06-09 住友橡胶工业株式会社 聚合物、橡胶组合物及使用该橡胶组合物的轮胎
JP6614014B2 (ja) * 2016-04-26 2019-12-04 信越化学工業株式会社 含窒素オルガノキシシラン化合物およびその製造方法
DE102017221259A1 (de) * 2017-11-28 2019-05-29 Evonik Degussa Gmbh Silanmischungen und Verfahren zu deren Herstellung
JP6865898B2 (ja) * 2017-12-21 2021-04-28 スリーエム イノベイティブ プロパティズ カンパニー シラン処理された表面を有する歯科用無機充填剤
CA3105394A1 (en) * 2018-07-02 2020-01-09 Aptamir Therapeutics, Inc. Targeted delivery of therapeutic agents to human adipocytes
AU2021403156A1 (en) * 2020-12-18 2023-07-13 Genevant Sciences Gmbh Peg lipids and lipid nanoparticles

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009209311A (ja) 2008-03-06 2009-09-17 Kao Corp 機能性物質放出剤
WO2012166949A1 (en) 2011-05-31 2012-12-06 Regents Of The University Of Minnesota Silicate prodrugs and nanoparticles
CN102911401A (zh) 2012-11-08 2013-02-06 广州市回天精细化工有限公司 一种羟基清除剂、其制备方法及含有它的硫化硅橡胶
CN108239103A (zh) 2018-01-02 2018-07-03 深圳市广业电子科技有限公司 一种含有多肟基硅的硅氮化合物

Also Published As

Publication number Publication date
JP2023513698A (ja) 2023-04-03
NZ791587A (en) 2025-06-27
CA3170547A1 (en) 2021-08-19
EP4103172A1 (en) 2022-12-21
WO2021163339A1 (en) 2021-08-19
EP4103172A4 (en) 2024-05-01
IL295441A (en) 2022-10-01
US20230139594A1 (en) 2023-05-04
MX2022009861A (es) 2022-11-07
BR112022015803A2 (pt) 2022-10-11
AU2021218409A1 (en) 2022-09-22
KR20220140531A (ko) 2022-10-18
CN115697321A (zh) 2023-02-03

Similar Documents

Publication Publication Date Title
US12350383B2 (en) Cationic lipids containing silicon
US12357705B2 (en) Negatively charged peg-lipid conjugates
JP7843707B2 (ja) 肝星細胞への治療薬の脂質ナノ粒子送達のためのカチオン性脂質
EP2279254B1 (en) Novel lipid formulations for nucleic acid delivery
JP7709981B2 (ja) 肝星細胞への治療薬の脂質ナノ粒子送達のためのカチオン性脂質
EP4466250A1 (en) Ionizable cationic lipids for lipid nanoparticles
US20240065982A1 (en) Lipid nanoparticles for delivering therapeutics to lungs
WO2025052278A1 (en) Pyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
EA050406B1 (ru) Катионные липиды, содержащие кремний

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260331

R150 Certificate of patent or registration of utility model

Ref document number: 7843707

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150